Last reviewed · How we verify
NCT05055713
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
NA trial testing Endoscopic therapy+ beta blockers in Liver Cirrhosis in 368 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 368 |
| Start date | 25 September 2020 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endoscopic therapy+ beta blockers
- Endoscopic therapy+ PSE+beta blockers
- Endoscopic therapy
- Endoscopic therapy+ PSE
- Endoscopic therapy+Somatostatin
- Endoscopic therapy+PSE+Somatostatin
Conditions studied
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
- Esophageal and Gastric Varices — all drugs for Esophageal and Gastric Varices →
- Hypersplenism — all drugs for Hypersplenism →
Sponsor
Qilu Hospital of Shandong University
Who can join
Adults 18 to 75, any sex, with Liver Cirrhosis or Esophageal and Gastric Varices. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to compare the effects of partial splenic artery embolization combined with endoscopic treatment and endoscopic treatment alone on portal hypertension in cirrhosis with hyperplenism or splenomegaly in esophageal and gastric varices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05055713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cirrhosis
Currently open trials in the same condition.
- NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
- NCT07325526 — A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- · Phase 2 · recruiting
- NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
- NCT07201649 — Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcificati · NA · recruiting
- NCT07252102 — Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients · NA · recruiting
Other Qilu Hospital of Shandong University trials
Trials by the same sponsor.
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
- NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
- NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
- NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
- NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05055713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
- Last refreshed: 2 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing